Fierce BioBiotech
Chutes & Ladders—Metsera acquisition architect swings to Structure
21 Apr 20260 views
Summary
After helping guide Metsera through its high-profile, $10 billion acquisition by Pfizer last year, Matthew Lang is swinging over to a different obesity biotech as chief operating officer and general counsel at Structure Therapeutics.
After helping guide Metsera through its high-profile, $10 billion acquisition by Pfizer last year, Matthew Lang is swinging over to a different obesity biotech as chief operating officer and general counsel at Structure Therapeutics.